KRAS and neoplasm: Our study showed IDH1/2 and KRAS mutation-carrying malignant cells presented dysregulated cuproptosis-associated genes, which may help to target tumor cells more precisely and avoid damage to beneficial cells (such as cytotoxic cells and normal HSPCs).57